‌

US Patent 10442815 Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors

Patent 10442815 was granted and assigned to Karus Therapeutics on October, 2019 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

Patent

Patent attributes

Patent Applicant

Karus Therapeutics

Current Assignee

Karus Therapeutics

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

104428150

Patent Inventor Names

Franck A. Silva0

Stephen J. Shuttleworth0

Alexander R. L. Cecil0

Alice E. Gatland0

Daniel J. Finnemore0

Rikki P. Alexander0

Date of Patent

October 15, 2019

Patent Application Number

157533580

Date Filed

August 19, 2016

Patent Citations

‌

US Patent 10035785 Phosphoinositide 3-kinase inhibitors

‌

US Patent 10087179 Fused tricyclic imidazole derivatives as modulators of TNF activity

Patent Citations Received

‌

US Patent 10668077 Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent

‌

US Patent 11779586 Compounds comprising tricyclic heterocyclic compounds

‌

US Patent 11708378 Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors

Patent Primary Examiner

‌

Alexander R Pagano

Patent abstract

The invention relates to a compound of formula I:

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10442815 Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API